Arca
Skip to content

Vasculitis

Drug research and approvals for vasculitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 185 studies of vasculitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, and FDA has 3 approved and 2 open orphan designations naming it.

  • Recruiting worldwide: 185
  • Trials authorized in Canada: 3
  • FDA orphan approvals: 3
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 185 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

7 in phase 3, 2 in phase 2, 5 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition
Avacopan
Phase 3 C5a anaphylatoxin chemotactic receptor antagonist
Azathioprine
Phase 3 Amidophosphoribosyltransferase inhibitor
Ibuprofen
Phase 3 Cyclooxygenase inhibitor
Methotrexate
Phase 3 Dihydrofolate reductase inhibitor
Prednisone
Phase 3 Glucocorticoid receptor agonist
Colchicine
Phase 3 Tubulin inhibitor
Belimumab
Phase 3 Tumor necrosis factor ligand superfamily member 13B inhibitor
Mycophenolate mofetil
Phase 2 Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
Cyclophosphamide anhydrous
Phase 2 DNA inhibitor
Alemtuzumab
Phase 1 CAMPATH-1 antigen inhibitor
Tacrolimus anhydrous
Phase 1 FK506-binding protein 1A inhibitor
Filgrastim
Phase 1 Granulocyte colony stimulating factor receptor agonist

How Its Trials Ended

253 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 40 whose ending is known, 38% met their primary endpoint, 5% missed it and 57% stopped early.

  • Ongoing9638%
  • Completed, result not reported7329%
  • Status unknown4417%
  • Met its primary endpoint156%
  • Stopped: other or unclear135%
  • Stopped: enrollment or feasibility62%
  • Stopped: funding31%
  • Missed its primary endpoint21%
  • Stopped: sponsor or business decision10%

Trials Authorized in Canada

Newest first; search them all in Canada trials
Nov 25, 2025A randomized, double blind, placebo controlled phase 4 clinical trial to evaluate the long-term safety and efficacy of avacopan in participants with…Avacopan (amg 569)AmgenPending
Aug 28, 2025Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of tarperprumig in adult…Tarperpruming (ALXN1820)AstraZeneca PharmaceuticalsOngoing
Oct 15, 2024A phase 3, open-label, uncontrolled single-arm study to evaluate the efficacy, pharmacokinetics, and safety of avacopan in combination with a rituximab or a…Avacopan (amg 569)AmgenOngoing

FDA Orphan Designations

Approved first, then open designations, newest first
Oct 7, 2021TavneosAs an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis…ChemoCentryx, Inc.Approved
Sep 27, 2019RituxanRITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with…Genentech, Inc.Approved
Apr 19, 2011RituxanFor the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and…Genentech, Inc.Approved
Feb 19, 2026A humanized IgG4 mAb that binds to hC5aR1 and blocks C5a…Treatment of anti-neutrophil cytoplasmic antibody-associated vasculitisOtsuka Pharmaceutical Development & Commercialization, IncDesignated
Sep 18, 2020GabexateTreatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitisRNR BioMedical Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.